{"id":"W7104179723","doi":"10.1016/j.annonc.2025.08.1382","title":"809P Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Cetuximab; Bevacizumab; Colorectal cancer; Safety profile; Chemotherapy; Chemotherapy regimen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004770192,0.0002046872,0.0005655341,0.0001773126,0.0001502247,0.0004559991,0.0002288723,0.000379619,0.004294178],"category_scores_gemma":[0.000777977,0.0001251828,0.0005556181,0.0002325673,0.0001813081,0.000335982,0.0001702652,0.0009239594,0.0005598563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005210208,"about_ca_system_score_gemma":0.0004642445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007883549,"about_ca_topic_score_gemma":0.002157403,"domain_scores_codex":[0.9998092,0.00006358203,0.00001236809,0.00003974933,0.00003684046,0.00003831926],"domain_scores_gemma":[0.999655,0.00008772658,0.0001166657,0.0000208004,0.00003103394,0.00008882223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2715029,0.003765267,0.06626444,0.001327812,0.002392657,0.001250025,0.0002128269,0.002327935,0.07556268,0.0005128988,0.008448103,0.5664324],"study_design_scores_gemma":[0.07127098,0.2996567,0.5186276,0.0005533193,0.005981875,0.01000514,0.0003810768,0.004896843,0.04523759,0.001175012,0.04208807,0.0001257532],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910189,0.004166841,0.0002387889,0.0004626189,0.00004018488,0.00006306078,0.001208864,0.00004516427,0.002755547],"genre_scores_gemma":[0.9956834,0.001325464,0.0001621181,0.0003648,0.00003421225,0.00003587986,0.0009499517,0.00001299919,0.001431278],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004294178,"threshold_uncertainty_score":0.01436549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0246460616700586,"score_gpt":0.3245464942917242,"score_spread":0.2999004326216656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}